7 March 2021 - Prophylaxis study
Association between Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) and Reduced Risk of Death in COVID-19 Patients: A Retrospective Cohort Study
et al., Pharmaceuticals, doi:10.3390/ph14030226 (Peer Reviewed)
Retrospective 350 COVID-19 hospitalized patients in Belgium, showing lower mortality with existing long-term FIASMA treatment, not quite reaching statistical significance for all FIASMA medications, but reaching statistical significance for amlodipine.
|
risk of death, 41.3% lower, RR 0.59, p = 0.06, treatment 93, control 257, odds ratio converted to relative risk, multivariable logistic regression, control prevalance approximated with overall prevalence.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. |
Darquennes et al., 3/7/2021, retrospective, Belgium, Europe, peer-reviewed, 4 authors.
Please send us
corrections, updates, or comments. Vaccines and treatments are both
valuable and complementary. All practical, effective, and safe means
should be used. Elimination of COVID-19 is a race against viral evolution. No
treatment, vaccine, or intervention is 100% available and effective for all
current and future variants. Denying the efficacy of any method increases
mortality, morbidity, collateral damage, and the risk of endemic status. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. WCH
and FLCCC provide
treatment protocols.